PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- JT/Torii License Menlo’s Pruritus Candidate for Japan Market
August 15, 2016
- Sawai Eyes First-to-File Status for 5 Generics in the US
August 10, 2016
- Japan PII Now Underway for Otsuka’s DMD Candidate TAS-205
August 10, 2016
- Otsuka Suffers Big Drops in Pharma Sales, Profit on US Abilify Patent Loss
August 10, 2016
- Astellas Files Japan NDA for Quetiapine for Bipolar Disorder
August 10, 2016
- Kissei, JCR Kick Off Japan PIII for Nesp Biosimilar
August 10, 2016
- Eisai, Biogen to Launch Global PIII for Alzheimer’s Drug by March-End
August 10, 2016
- Ono Rushes to Soothe Investor Nerves over Opdivo PIII Data
August 10, 2016
- Opdivo Disappoints in 1st-Line Lung Cancer Trial
August 9, 2016
- Carna Biosciences, Janssen Call Off Licensing Deal for Kinase Inhibitor
August 8, 2016
- Takeda, Pfizer to Wind Up Sales Deal for Prevenar, BeneFIX
August 8, 2016
- Meiji Seika Pharma Licenses Therapeutic Candidate Substance for Multiple Sclerosis to Curadim Pharma
August 8, 2016
- Astellas to Transfer US Manufacturing Unit to Avara
August 5, 2016
- Sumitomo Dainippon to Nurture Specialized Reps as It Pushes Oncology, Other Biz Focus
August 5, 2016
- Rohto, Osaka Univ. Tie Up for Stem Cell Research, Aim for Approval of Regenerative Medicine Products
August 5, 2016
- Zafatek Most Heavily Promoted Drug in GP Market in June: Anterio
August 4, 2016
- Teijin Jettisons Extended-Release Version of Feburic; Successor Now in PI
August 3, 2016
- Mitsubishi Tanabe Erases Alzheimer’s Drug from Japan Pipeline
August 3, 2016
- Adcetris Shows Positive Efficacy Profile in Cutaneous T-Cell Lymphoma
August 3, 2016
- Takeda’s Cx601 Stem Cell Therapy Hits Primary Endpoint in Global PIII
August 3, 2016
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…